Kamada Reports Strong Q3 Earnings, Raises Annual Forecasts and Declares Dividend
Translated & summarized from Ice by baba
Israeli biopharmaceutical company Kamada reported a 51% increase in net profit to $8 million for its third quarter of 2026, with revenues rising 11% to $52 million. The company raised its annual revenue forecast and declared a dividend of $8 million. Kamada expects continued double-digit growth in 2027.
The story in 5 lines · by baba
- Kamada's Q3 net profit jumped 51% to $8 million on 11% higher revenues of $52 million.
- The company raised its 2026 revenue forecast to $205-$208 million.
- Kamada declared an $8 million dividend, bringing the annual total to $32.2 million.
- Adjusted EBITDA grew 30% to $15.2 million, with margins improving.
- Sales of KEDRAB for rabies treatment drove much of the product revenue increase.
Israeli biopharmaceutical company Kamada, traded on the Tel Aviv and Nasdaq stock exchanges, announced its third-quarter 2026 financial results on Monday, revealing significant growth in revenue and profitability. The company, controlled by the FIMI fund, reported revenues of $52 million for the quarter, an 11% increase from $47 million in the same period last year. Net profit surged by 51% to $8 million, up from $5.3 million in the prior year's quarter, with earnings per share rising from 9 to 14 cents. Adjusted EBITDA grew 30% to $15.2 million, representing 29% of revenues compared to approximately 25% last year. This improvement was primarily driven by increased sales of the company's products, notably KEDRAB, used for post-exposure rabies treatment in the US market, alongside higher sales of VARIZIG and HEPAGAM. The gross profit margin improved from 42% to 45%, partly due to a more profitable sales mix.
Following these strong results, Kamada raised its full-year 2026 revenue forecast to a range of $205 million to $208 million, an increase from the previous projection of $200 million to $205 million. The adjusted EBITDA forecast was also boosted to $52 million to $54 million, up from $50 million to $53 million. The company anticipates continued double-digit growth in revenue and profitability for 2027 and plans to release a detailed numerical forecast in January. For the first nine months of the year, revenues reached a record $152.2 million, a 12% increase, and net profit grew 29% to $21.4 million. Cash flow from operating activities more than doubled to $37.6 million.
In parallel with its financial announcements, Kamada declared a dividend of 14 cents per share, totaling approximately $8 million. Including previous distributions, the cumulative dividend for the year will reach $32.2 million.